| Patient | Sun Yat-sen |
|---|---|
| Date of birth | 1968-11-12 |
| Identifiers | MRN HR-ET016-SYN; SSN (made up) 000-16-4183 |
| Document date | 2026-05-18 |
| Author | Wen-Li Huang, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Results of the liver mass work-up and medical oncology consultation. [S]
Mr. Sun returns two weeks after his first visit and is seen the same day by Dr. Choi of medical oncology. He had the multiphase CT eleven days ago, the MRI with MRCP a week ago and the ultrasound-guided core biopsy five days ago; the biopsy site was sore for a day. He asked to see the images and went through them with Dr. Huang and Dr. Choi. The ache under his right ribs is 2 of 10 on acetaminophen once or twice a day, and he is eating five small meals a day. He has had no jaundice, itching, dark urine, fever or vomiting. He is still working full days and asked for a plain account of the findings and the choices. [S]
| Element | Detail |
|---|---|
| Tests done | Multiphase CT, MRI with MRCP, core biopsy of the liver mass |
| Pain | 2 of 10 on acetaminophen once or twice a day |
| Appetite and weight | Five small meals a day; weight 60.6 kg |
| Associated signs and symptoms | No jaundice, itching, dark urine, fever, or vomiting |
| His request | To see the images and hear the findings and choices plainly |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Weight down a further 0.4 kg; tired in the evenings; no fever |
| Gastrointestinal | Positive | Ache under the right ribs, 2 of 10; early fullness; no vomiting, jaundice, or pale stools |
| Respiratory | Negative | No cough or breathlessness |
| Integumentary | Negative | No itching; biopsy site healed |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for right upper abdominal ache; no more than 3,000 mg a day | Two tablets by mouth every 8 hours as needed, no more than 3,000 mg a day | Oral route | 2026-05-04 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-18 | Body height | 165 | cm | S |
| 2026-05-18 | Body weight | 60.6 | kg | S |
| 2026-05-18 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 2026-05-18 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-05-18 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-05-18 | Heart rate | 86 | /min | S |
| 2026-05-18 | Respiratory rate | 16 | /min | S |
| 2026-05-18 | Body temperature | 36.8 | Cel | S |
| 2026-05-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-18 | ECOG Performance Status score | 1 | {score} | S |
Vital signs recorded on 2026-05-18; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Thin, well; blood pressure 128/82, pulse 86; weight 60.6 kg; no jaundice |
| Abdomen | Firm, non-tender mass felt 4 cm below the right costal margin, moving with breathing; no ascites; no splenomegaly |
| Lymph nodes | No supraclavicular or umbilical nodes |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Right upper quadrant abdominal mass with weight loss: a dull ache under the right ribs and early fullness for about three months, 4 kg weight loss, and a firm, non-tender mass felt 4 cm below the right costal margin; no jaundice, fever, or itching. Ultrasound today: a 6.8 cm solid, heterogeneous mass in liver segments IV and V that cannot be separated from the gallbladder, which contains stones; the rest of the liver is smooth, with no ascites. Multiphase CT, tumor markers, hepatitis serology and medical oncology consultation arranged | resolved | confirmed | R19.01 | S — Synthetic presenting problem anchored to the documented right upper abdominal mass; superseded by the biopsy diagnosis. |
| Adenocarcinoma of the gallbladder invading the liver: core biopsy of the liver mass shows moderately differentiated adenocarcinoma (CK7 positive, CK20 and CDX2 negative), and multiphase CT and MRI show a 7.1 cm mass arising from the gallbladder fundus and invading liver segments IVb and V, with gallstones and two enlarged nodes in the hepatoduodenal ligament; no cirrhosis; alpha-fetoprotein normal, CA 19-9 raised. Clinical T3 N1 before staging laparoscopy (AJCC 8th edition). Synthetic modern episode linked to his documented final illness, described in life as liver cancer and at autopsy as gallbladder adenocarcinoma | active | confirmed | C23 | S — Synthetic modern diagnosis chosen to fit the documented findings: a mass involving the liver at operation and gallbladder adenocarcinoma at autopsy. |
| Resolved hepatitis B infection: hepatitis B surface antigen negative, total core antibody positive, surface antibody positive, HBV DNA undetectable; hepatitis C antibody negative. At risk of reactivation during chemotherapy and immunotherapy; monitored | active | confirmed | Z86.19 | S — Synthetic serology; not a claim that he had hepatitis B in his lifetime. No fetched source mentions hepatitis. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Multiphase contrast CT or MRI of the liver | At presentation of a liver mass | Completed today | Mass arises from the gallbladder and invades segments IVb and V; non-cirrhotic liver; no other liver lesions |
| Imaging | CT of the chest, abdomen and pelvis | At staging, then every 2 to 3 months on treatment | Completed today | Two enlarged hepatoduodenal ligament nodes; no distant disease on CT; 6 mm calcified lung granuloma |
| Laboratory | Core biopsy of the mass | When imaging cannot make the diagnosis (non-cirrhotic liver) | Completed today | Adenocarcinoma, CK7 positive, CK20 and CDX2 negative: pancreatobiliary origin |
| Laboratory | Alpha-fetoprotein | At presentation of a liver mass | Up to date | 3.2 ng/mL at intake; normal |
| Laboratory | CA 19-9 (and CEA when raised) | At diagnosis, then with each cycle or restaging | Up to date | CA 19-9 412 U/mL and CEA 8.6 ng/mL at intake |
| Laboratory | Liver function: Child-Pugh and ALBI | At diagnosis, then before each treatment decision | Completed today | Child-Pugh A6; ALBI grade 2; bilirubin 0.9 mg/dL and INR 1.0 at intake |
| Laboratory | Hepatitis B and C serology | Before chemotherapy or immunotherapy | Completed today | Surface antigen negative, core antibody positive, surface antibody positive, HBV DNA undetectable; hepatitis C antibody negative |
| Survey | ECOG performance status | Every visit | Completed today | ECOG 1 |
| Examination | Weight and nutrition | Every visit | Completed today | 60.6 kg, down 0.4 kg in two weeks; dietitian booked |
| Survey | Pain | Every visit | Completed today | 2 of 10 on acetaminophen |
| Referral | Multidisciplinary tumor board | Before treatment of a biliary tract cancer | Ordered | In two days |
| Imaging | Staging laparoscopy | Before resection of gallbladder cancer | Ordered | In about ten days, with a port |
| Laboratory | Comprehensive genomic profiling of tumor tissue | At diagnosis of advanced disease | Ordered | Sent on the biopsy tissue |
| Referral | Medical oncology | At diagnosis | Completed today | Seen by Dr. Choi today |
| Referral | Specialist palliative care | From the diagnosis of advanced cancer | Due | Introduced today; first meeting after staging, at his choice |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers (2026); AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023); Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (2020); Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017)
Follow-up: Tumor board in two days; staging laparoscopy in about ten days. Visit in two weeks with the result and the tumor board recommendation. Next scheduled visit 2026-06-01: staging laparoscopy result and tumor board recommendation; first cycle of chemoimmunotherapy and specialist palliative care. [S]